NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 10 August 2023

**Location:** Manchester/Zoom (hybrid)

## Attendees

Committee members present

1. Dr Megan John (Chair) Present for all items
2. Dr Stephen Smith (Vice-chair) Present for all items
3. Martin Bradley Present for all items
4. Elliott Dash Present for all items
5. Professor Sofia Dias Present for all items
6. Professor Rachel Elliott Present for all items
7. Andrew Fox Present for all items
8. Dr Andrew Hitchings Present for all items
9. Dr Robert Hodgson Present for all items
10. Dr Bernard Khoo Present for all items
11. Dr Ivan Koychev Present for all items
12. Dr Philip Mallender Present for all items
13. Professor David Meads Present for all items
14. Dr Nathan Moore Items 1.1 to 3.2.2
15. Dr Malcolm Oswald Present for all items
16. Carole Pitkeathley Present for all items
17. Dr Raju Reddy Present for all items
18. Dr Ben Searle Present for all items
19. Professor John Watkins Present for all items

NICE staff (key players) present

Jasdeep Hayre, Associate Director Present for all items

Celia Mayers, Project Manager Present for all items

Alan Moore, Heath Technology Assessment Adviser Items 1.1 to 3.2.2

Ross Wilkinson, Heath Technology Assessment Analyst Items 1.1 to 3.2.2

Rufaro Kausi, Heath Technology Assessment Adviser Items 4.1.1 to 4.2.2

Cara Gibbons, Heath Technology Assessment Analyst Items 4.1.1 to 4.2.2

Jacoline Bouvy, Programme Director Present for all items

External assessment group representatives present

|  |  |
| --- | --- |
| Keith Cooper, Southampton Health Technology Assessments Centre | Items 1.1 to 3.1.3 |
| Joanna Picot, Southampton Health Technology Assessments Centre | Items 1.1 to 3.1.3 |
| Nicole Downes, BMJ Group | Items 4.1.1 to 4.1.3 |
| Steve Edwards, BMJ Group | Items 4.1.1 to 4.1.3 |
| Isaac Mackenzie, BMJ Group | Items 4.1.1 to 4.1.3 |

Clinical, Patient & NHS England experts present

|  |  |
| --- | --- |
| Frances Copeland, Patient expert, nominated by Muscular Dystrophy UK | Items 1.1 to 3.1.3 |
| Penelope Henrion, Patient expert, nominated by myaware | Items 1.1 to 3.1.3 |
| Channa Hewamadduma, Consultant Neuromuscular Neurologist and Honorary Senior Lecturer – clinical expert, nominated by Argenx | Items 1.1 to 3.1.3 |
| Fiona Norwood, Consultant Neurologist – clinical expert, nominated by myaware | Items 1.1 to 3.1.3 |
| Sanjeev Patel, NHS England Innovative Medicines Fund clinical lead | Items 1.1 to 3.2.2 |
| Andy Bloor, Senior Lecturer – patient expert, nominated by The Migraine Trust | Items 4.1.1 to 4.1.3 |
| Deborah Sloan, Writer/Therapist – patient expert, nominated by The Migraine Trust | Items 4.1.1 to 4.1.3 |
| Brendan Davies, Consultant Neurologist – clinical expert, nominated by Association of British Neurologists | Items 4.1.1 to 4.1.3 |
| David Kernick, GP with special interest in headache – clinical expert, nominated by Teva UK | Items 4.1.1 to 4.1.3 |

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair, Dr Megan John, welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Chris Parker, Christopher Herring, Giles Monnickendam, Dr Guy Makin, Dr Matthew Bradley and Dr Rebecca Payne.

### News and announcements

* 1. None

### Appraisal of Efgartigimod for treating generalised myasthenia gravis [ID4003]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Argenx.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10986).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Malcolm Oswald, Dr Bernard Khoo and Sofia Dias.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10986>

### Appraisal of rimegepant for treating acute migraine [ID1539]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Pfizer
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10839).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the Chair.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10839>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Wednesday 13 September 2023 and will start promptly at 9:00am.